linjc16/ctgov huggingface dataset:
Predicting the Severity of Post-cesarean Wound Infections Using Serum Procalcitonin Levels

Study Overview
=================
Brief Summary
-----------------
The serum procalcitonin levels are important during infections and sepsis. The investigators aimed to assess its predictive value in terms of post-cesarean wound infection.

Detailed Description
-----------------
The serum procalcitonin levels are important during infections and sepsis. Recent studies showed that serum procalcitonin levels are more sensitive than serum CRP levels.The investigators aimed to assess its predictive value in terms of post-cesarean wound infection. The serum procalcitonin levels are aimed to measure in participants who had cesarean section and developed surgical site infection. The investigators aimed to compare the serum procalcitonin levels between the patients who need secondary suture and the patients who did not need secondary suture.

Official Title
-----------------
Predicting the Severity of Post-cesarean Wound Infections Using Serum Procalcitonin Levels

Conditions
-----------------
Wound Infection, Cesarean Wound Disruption

Intervention / Treatment
-----------------
* Other: procalcitonin level


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: who developed surgical site infection after their cesarean sections. 18-40 years old Exclusion Criteria: history of chorioamnionitis and premature rupture of membranes urinary tract infections any infectious condition other than surgical site infection

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| No secondary suture<br>The participants who developed post-cesarean surgical site infection and follow-up only antibiotic treatment for their wound care. | Other: procalcitonin level<br>* serum procalcitonin level will be measured in both groups.<br>|
| Secondary suture<br>The participants who developed post-cesarean surgical site infection and need a secondary suture for their wound care | Other: procalcitonin level<br>* serum procalcitonin level will be measured in both groups.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Serum procalcitonin levels in participants who developed wound infection after cesarean sections | Serum procalcitonin levels will be measured in participants who will develop post-cesarean wound site infections. The serum procalcitonin levels will be compared in subgroups who need secondary suture and those who don't require suturing | 5 months |
The Relationship Between the Flow of Arteriovenous Fistula and Cardiac Function in Haemodialysis Patients

Study Overview
=================
Brief Summary
-----------------
A prospective longitudinal surveillance for a period of 2 months. Sample - identify suitable Chronic Kidney Disease (CKD) patients who undergo HD with functioning AVF. Participants at various age range and both sexes are recruited to observe their access flow, access recirculation and cardiac function and assess their relationship.

Detailed Description
-----------------
All patients recruited who met the inclusion criteria were investigated access flow, access recirculation and cardiac function(including cardiac output,cardiac index,central blood volume,et al).Measurement time is the beginning of HD session (first 30min to 1 hr),Middle of HD session (optional),and the end of the HD session (1hr to 30 min prior to end of session). The follow-up duration is 6 months and 12 months.Repeat the assessment at the above time points.

Official Title
-----------------
Study of Access Flow ,Access Recirculation of Arteriovenous Fistula and the Relationship With Cardiac Function

Conditions
-----------------
Complication of Hemodialysis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients undergo HD with native AVF AF of AVF between 300ml/min and 1800ml/min Exclusion Criteria: Patients whose AVF developed Access Recirculation (AR) which cannot be resolved at the time of measurement Patients developed access or systemic infection during the study period

Ages Eligible for Study
-----------------
Minimum Age: 16 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| to access the chang of the fistula blood flow in HD patients using Ultrasound Dilution method |  | Change of the fistula blood flow from baseline to 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Changes of the Cardiac Index (CI) during the course of hemodialysis therapy |  | from baseline to 6 months | 
| Changes of the Oxygen delivery ( Adequacy of hemoglobin level to Epoetin) during the course of hemodialysis therapy |  | from baseline to 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
access flow, access recirculation, cardiac output, cardiac index, hemodialysis
A Prospective Observational Case Series of a Four-ring-haptic Acrylic One-piece IOL

Study Overview
=================
Brief Summary
-----------------
To describe biocompatibility, postoperative results and complications after implantation of the Corneal Quatrix Evolutive (Corneal, Croma, Austria) intraocular lens, a hydrophilic acrylic intraocular lens (IOL) with 4-haptic design and 360° sharp optic edge.

Detailed Description
-----------------
In this prospective case series the Corneal Quatrix Evolutive IOL was implanted in 14 eyes of nine patients with senile cortico-nuclear cataract. A standardized surgical technique and post-operative regimen were applied. Six months postoperatively best corrected visual acuity (BCVA), refraction and complications (especially) posterior capsule opacification (PCO) were analysed.

Official Title
-----------------
Observational Case Series of the Implantation of Intraocular Lens QUATRIX® Aspheric Evolutive Pre-loaded.

Conditions
-----------------
Cataract

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with senile cortico-nuclear cataracts without previous intraocular surgery Exclusion Criteria: Dilated pupil size of < 6 mm long-term anti-inflammatory treatment previous history of intraocular surgery previous history of corneal endothelial damage previous history of ocular trauma traumatic cataract history of uveitis diabetic retinopathy advanced macular degeneration

Ages Eligible for Study
-----------------
Minimum Age: 50 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients with senile cataract<br>Patients with senile cataract | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Best-corrected visual acuity (BCVA) | The best-corrected visual acuity is assessed with glasses after cataract operation | Six months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Posterior capsule opacification | The posterior capsule opacification is assessed by slit lamp examination and subjective grading | Six months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Best-corrected visual acuity, posterior capsule opacification, QUATRIX® Aspheric Evolutive pre-loaded
Effects of Fingolimod on Heart Rhythm and Heart Rate Variability in Patients With Multiple Sclerosis

Study Overview
=================
Brief Summary
-----------------
The current study sought to prolong the observational interval after initiating medication with fingolimod and to measure the long-term effects of fingolimod on HR and HRV as an indicator of autonomic nervous system function in patients with RR-MS.

Detailed Description
-----------------
Fingolimod (Gilenya®; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA) is a novel oral disease-modifying therapy that acts as a sphingosine-1-phosphate (S1P) receptor agonist and reduces the recirculation of lymphocytes to blood and peripheral tissues, including inflammatory lesions. A critical part of fingolimod therapy still remains in the screening and initiation phases because of the risk of cardiac events. It is well known that the first dose of fingolimod is associated with a decrease in heart rate (HR) and slowing of atrioventricular (AV) conduction. Patients were continuously observed for a minimum of 6 hours after taking fingolimod. Because resurgence of heart rate began at 6 hours, the actual recommendation for observation is only 6 hours. Data about the effect of fingolimod after this time period is lacking.

Official Title
-----------------
FINGORHYMS - Effects of Fingolimod on Heart Rhythm and Heart Rate Variability in Patients With Multiple Sclerosis

Conditions
-----------------
Multiple Sclerosis

Intervention / Treatment
-----------------
* Drug: Gilenya®; Novartis Pharmaceuticals Corporation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Ability to provide written informed consent in accordance with Good Epidemiological Practice and local legislation Individuals over the age of 18 years Patients with relapsing-remitting forms of multiple sclerosis who were considered eligible for fingolimod treatment on a clinical basis. Exclusion Criteria: Insufficient knowledge of the German language (not able to understand and write the German language) Physical or psychological incapability to take part in the study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Gilenya®; Novartis Pharmaceuticals Corporation|This is a prospective cohort-based study. Eligible are all patients planned for a treatment with fingolimod at the Hamburg University Hospital who are willing and able to participate in an observational study.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Recurrence of AF | Recurrence of sustained atrial fibrillation (>30 seconds) after atrial fibrillation ablation | 6 months follow up | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Heart Rhythm, Fingolimod, autonomic nervous system, Effects of Medicinal Substance
Effectiveness of a Novel Concept for a Manual Toothbrush Broscyl®

Study Overview
=================
Brief Summary
-----------------
The aim is to determine the efficacy and the satisfaction/adaptability of the manual Broscyl® toothbrush as compared with a standard  soft  manual toothbrush ADA (American Dental Association) reference using the modified Stillman brushing technique, in children, adults and elderly persons, after 3 months of daily use.

Official Title
-----------------
Effectiveness and Satisfaction-adaptability of a Novel Concept for a Manual Toothbrush Broscyl®: Randomised Clinical Trial in Children, Adults and Elderly People

Conditions
-----------------
Healthy Subjects

Intervention / Treatment
-----------------
* Device: Manual toothbrush reference
* Procedure: Measure of the dental plaque
* Device: Manual toothbrush Broscyl®


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Children attending school aged between 8 and 15 years OR adults aged from 18 to 45 years OR elderly persons aged more than 65 years old Presenting at least one incisive, one canine, one premolar and one molar in each quadrant Able to brush their own teeth at least twice a day Persons who have provided written informed consent Persons covered by the national health insurance agency Exclusion Criteria: Persons with acute periodontal disease Persons in a period of postsurgical healing Persons with an acute oral pain syndrome Persons undergoing orthodontic treatment with a fixed brace Persons not covered by the national health insurance agency Pregnant women The use of adjuvants

Ages Eligible for Study
-----------------
Minimum Age: 8 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Children<br> | Device: Manual toothbrush reference<br> <br> Procedure: Measure of the dental plaque<br> <br> Device: Manual toothbrush Broscyl®<br> <br> |
| Other: Adults<br> | Device: Manual toothbrush reference<br> <br> Procedure: Measure of the dental plaque<br> <br> Device: Manual toothbrush Broscyl®<br> <br> |
| Other: Elderly people<br> | Device: Manual toothbrush reference<br> <br> Procedure: Measure of the dental plaque<br> <br> Device: Manual toothbrush Broscyl®<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Measurement of the dental plaque index |  | up to 3 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Patient satisfaction | self-completed questionnaire | up to 3 months |
Alpha-defensin as a Diagnostic Means to Distinguish Between Acute Bacterial and Viral Infections

Study Overview
=================
Brief Summary
-----------------
This study aims to investigate the use of alpha-defensin as a diagnostic means to distinguish between acute bacterial and viral infections.

Official Title
-----------------
Alpha-defensin as a Diagnostic Means to Distinguish Between Acute Bacterial and Viral Infections

Conditions
-----------------
Bacterial Infections, Viral Infection

Intervention / Treatment
-----------------
* Diagnostic Test: Laboratory blood test


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Children with either bacterial or viral infections Exclusion Criteria: All others

Ages Eligible for Study
-----------------
Minimum Age: 1 Year
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Viral infection<br>Patients with proven viral infections will have laboratory blood test taken | Diagnostic Test: Laboratory blood test<br>* Laboratory blood test will be analyzed to determine whether there is a rise in alpha-defensin<br>|
| Bacterial Infection<br>Patients with proven bacterial infections will have laboratory blood test taken | Diagnostic Test: Laboratory blood test<br>* Laboratory blood test will be analyzed to determine whether there is a rise in alpha-defensin<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Rise in alpha-defensin | Laboratory blood tests will be analyzed to determine whether there is a rise in alpha-defensin levels in bacterial infections as compared to viral infections. | One year |
Electroencephalogram During Desflurane Anaesthesia

Study Overview
=================
Brief Summary
-----------------
To study the behavior of EEG during changing desflurane concentrations.

Detailed Description
-----------------
The concentration of desflurane will be increased to burst suppression EEG level, and thereafter decreased.

Official Title
-----------------
Electroencephalogram During Increasing and Decreasing Desflurane Concentration

Conditions
-----------------
Anesthesia

Intervention / Treatment
-----------------
* Other: desflurane


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: adult patients Exclusion Criteria: pediatric patients

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| No Intervention: desflurane<br>inhalation concentration | Other: desflurane<br>* changing concentration<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The behavior of EEG indices numbers during the course of anesthesia, with comparison to raw EEG traces | How do the EEG indices reflect the clinical evaluation of anesthetic state and the visual appearance of EEG | participants will be followed for the duration of surgical anesthesia, an expected average of 1 hour | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
desflurane, electroencephalogram
Early Versus Late Interval Postpartum Copper Intrauterine Device Insertion

Study Overview
=================
Brief Summary
-----------------
The optimal interval between pregnancies is debated, but a duration greater than 11-18 months has been suggested as reducing complications in the subsequent pregnancy. Improved birth spacing can be a key benefit use of long-acting reversible contraception, but delay to initiation can still be problematic.So women who have recently given birth can be cost-effectively targeted for family planning education and engagement because often they are already connected with health professionals

Official Title
-----------------
Early (4th Week) Versus Late (6thweek) Interval Postpartum Copper Intrauterine Device Insertion: a Randomized Controlled Trial

Conditions
-----------------
Contraception Behavior

Intervention / Treatment
-----------------
* Procedure: early insertion
* Procedure: late insertion


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Delivered (vaginal or Cesarean) a singleton living baby ≥28weeks gestation. Women desire birth spacing for one year or more. Women who will accept to participate in the study and follow up. Exclusion Criteria: Known uterine anomalies. Women with previous ectopic pregnancy. Presence of postpartum pyrexia. Women with history of postpartum hemorrhage in the last delivery either primary or secondary. Retained products of conception. History of previous uterine perforation. Anticipation of difficulty of subsequent follow-up with the women. Women with uncontrolled diabetes and hypertension. Women who wish to use other contraceptive methods.

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Health Services Research
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: insertion by the end of the 4th week postpartum<br> | Procedure: early insertion<br>* insertion at 4th postpartum week<br>|
| Active Comparator: insertion by the end of the 6th week postpartum<br> | Procedure: late insertion<br>* insertion at 6th postpartum week<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The number of participants use the device | number of women place the intrauterine device within 6 weeks | 6 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
intrauterine device
Turkish Validation Study of Endometriosis Health Profile -30 (EHP-30) Test

Study Overview
=================
Brief Summary
-----------------
For the Turkish validation Study of the Endometriosis Health Profile test (EHP-30) consisting of 30 questions, this 30-question test will be applied to 228 patients after 2 different translations to be applied after the translation of this 30-question test sworn translator to the patients who have been surgically diagnosed with endometriosis.

Detailed Description
-----------------
The appointment of the patients consists of patients who were surgically diagnosed with Endometriosis in our clinic. English and Turkish translation will be verified after 2 different sworn translators.

Official Title
-----------------
Turkish Validation of Endometriosis Health Profile -30 (EHP-30) Test

Conditions
-----------------
Endometriosis

Intervention / Treatment
-----------------
* Other: Endo Patients with Endometriosis Health Profile -30 (EHP-30) Test


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: being surgically diagnosed with endometriosis Age between 18- 45 not being pregnant Exclusion Criteria: have been diagnosed with endometriosis by ultrasound above 45 and under 18 years old use psichiatrig drugs being diagnosed with a psychiatric illness

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Endo Patients with Endometriosis Health Profile -30 (EHP-30) Test|The appointment of the patients consists of patients who were surgically diagnosed with Endometriosis in our clinic.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Turkish Validation of Endometriosis Health Profile -30 (EHP-30) Test | The Turkish validation study of the Endometriosis Health Profile -30EHP-30 test, which shows the general quality of life of endometriosis patients, will be performed and the use of Turkish language will be provided. | 3 months |